Purchase Order 75N91018P00420

<p>The National Cancer Institute awarded a purchase order to Bio-Rad Laboratories, Inc. for $5,310.80 on August 28, 2017, with ultimate completion on July 16, 2018. The order is for life science research supplies and equipment sourced from Bio-Rad's Life Science Group Division. Place of performance is Bethesda, Maryland. No set-aside was used; the award carries firm fixed-price pricing on a full-and-open competitive basis.</p>

<p>The National Cancer Institute awarded a purchase order to Bio-Rad Laboratories, Inc. for $19,428 on September 12, 2018, with an ultimate completion date of September 28, 2019. Work is performed at the awardee's location in Bethesda, Maryland. The order covers life science research instrumentation and related supplies on a firm fixed-price basis. No set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Bio-Rad Laboratories, Inc. for $8,544.00 on November 8, 2017, with ultimate completion November 7, 2018. Performance takes place in Bethesda, Maryland. The order covers life science research instrumentation and related supplies on a firm fixed-price basis. No set-aside applies.</p>

<p>The National Cancer Institute issued a purchase order to Bio-Rad Laboratories, Inc. for $7,500.00 on August 9, 2017, with ultimate completion by August 13, 2018. No set-aside was used. Place of performance is Bethesda, Maryland. The order is for life science research equipment or related supplies and services from Bio-Rad's Life Science Group Division.</p>

<p>The National Cancer Institute awarded a purchase order to Bio-Rad Laboratories, Inc. for $219,240.50 on August 27, 2014, with an ultimate completion date of August 26, 2015. No set-aside was used. Performance takes place in Bethesda, Maryland. The order is priced on a firm fixed-price basis. The source does not specify the particular equipment, supplies, or services procured under this order.</p>

<p>The National Cancer Institute awarded a purchase order to Bio-Rad Laboratories, Inc. on August 16, 2016, with a ceiling value of $3,657.02 and an ultimate completion date of September 16, 2017. The order is firm fixed price with no set-aside. Work is performed in Bethesda, Maryland. Bio-Rad supplied laboratory equipment and instrumentation to support the Institute's research operations.</p>

<p>The National Cancer Institute awarded a purchase order to Bio-Rad Laboratories, Inc. (Life Science Group Division) for $4,151.40 on April 18, 2018, with ultimate completion on April 25, 2019. No set-aside was used. Performance occurred in Bethesda, Maryland. The order was issued as a firm fixed-price service contract renewal. Specific commodities or services procured are not detailed in the source.</p>

The National Cancer Institute awarded a purchase order to Bio-Rad Laboratories, Inc., Life Science Group Division, on September 5, 2018, with a ceiling value of $11,320.28 and an ultimate completion date of September 4, 2019. No set-aside was used. Performance occurs in Bethesda, Maryland. The order is firm fixed price, covering life science research and clinical diagnostic equipment, reagents, or maintenance services characteristic of Bio-Rad's federal portfolio in analytical laboratory...

The National Cancer Institute awarded a purchase order to Bio-Rad Laboratories, Inc. on May 30, 2018, valued at $5,604.00 for life science research equipment and supplies, with ultimate completion on May 31, 2019. The order carries firm fixed-price pricing with no set-aside. Performance takes place in Bethesda, Maryland. Bio-Rad Laboratories is a for-profit manufacturer of polymerase chain reaction systems, droplet digital PCR instruments, and related laboratory consumables and maintenance...

<p>The National Cancer Institute issued a purchase order to Bio-Rad Laboratories, Inc. valued at $7,672.44 on August 9, 2016, with final completion scheduled for August 14, 2017. Work is performed at Bio-Rad's facility in Bethesda, Maryland. The order covers laboratory equipment, reagents, or consumables supplied on a firm fixed-price basis. No small business set-aside was applied.</p>